MeSH term
Frequency | Condition_Probility | Female | 18 | 0.0 |
Humans | 54 | 0.0 |
Male | 26 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 49 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 22 | 0.0 |
Animals | 24 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 5 | 0.0 |
*Proto-Oncogenes | 42 | 6.0 |
Transcription Factors/genetics/*metabolism | 4 | 0.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Adult | 21 | 0.0 |
*Chromosomes, Human, Pair 12 | 3 | 1.0 |
*Chromosomes, Human, Pair 3 | 14 | 3.0 |
DNA-Binding Proteins/*genetics | 11 | 0.0 |
Gene Expression | 8 | 0.0 |
In Situ Hybridization, Fluorescence | 10 | 0.0 |
Leukemia, Myeloid, Chronic/*genetics | 2 | 3.0 |
Oncogene Proteins, Fusion/*genetics | 2 | 1.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
*Transcription Factors | 25 | 1.0 |
Translocation, Genetic | 7 | 0.0 |
Antigens, Ly/genetics | 2 | 22.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Membrane Proteins/genetics | 3 | 0.0 |
Mice | 20 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Acute Disease | 8 | 0.0 |
*Neoplasm Proteins | 3 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Zinc Fingers | 7 | 1.0 |
Genetic Vectors | 2 | 0.0 |
Retroviridae | 2 | 2.0 |
Time Factors | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
Cell Line | 7 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Mutation | 4 | 0.0 |
Nuclear Proteins/*metabolism | 2 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Transfection | 5 | 0.0 |
Up-Regulation | 3 | 0.0 |
Immunophenotyping | 2 | 0.0 |
Karyotyping | 14 | 0.0 |
*Proto-Oncogene Proteins | 10 | 0.0 |
Transcription Factors/*genetics | 5 | 0.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Base Sequence | 19 | 0.0 |
Molecular Sequence Data | 23 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Aged | 9 | 0.0 |
Chimeric Proteins/biosynthesis/*genetics | 2 | 50.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 4 | 4.0 |
English Abstract | 2 | 0.0 |
Middle Aged | 18 | 0.0 |
Myelodysplastic Syndromes/genetics/*metabolism | 2 | 66.0 |
*Oncogene Proteins, Fusion | 8 | 28.0 |
Adolescent | 3 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Transcription Factors/genetics/*physiology | 2 | 1.0 |
Amino Acid Sequence | 9 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
Consensus Sequence | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics | 2 | 1.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
*Translocation, Genetic | 17 | 1.0 |
3T3 Cells | 4 | 0.0 |
Leukemia Virus, Murine/*genetics | 2 | 13.0 |
Cell Differentiation | 4 | 0.0 |
Cell Division | 3 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Chimeric Proteins/genetics/metabolism | 3 | 3.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 3/*genetics | 6 | 2.0 |
DNA-Binding Proteins/*genetics/*metabolism | 2 | 1.0 |
*Gene Expression | 2 | 0.0 |
Leukemia, Myeloid/*genetics/metabolism/pathology | 2 | 25.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Leukemia, Myeloid/*genetics | 4 | 2.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Clone Cells | 2 | 0.0 |
Chromosomes, Human, Pair 21 | 2 | 1.0 |
Chromosomes, Human, Pair 3 | 6 | 3.0 |
*DNA-Binding Proteins | 4 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Comparative Study | 4 | 0.0 |
Exons | 4 | 0.0 |
Transcription Factors/*biosynthesis/genetics | 2 | 2.0 |
Fatal Outcome | 2 | 0.0 |
Gene Expression Regulation, Leukemic | 7 | 7.0 |
Prognosis | 5 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
Syndrome | 3 | 0.0 |
Leukemia, Myelocytic, Acute/genetics | 2 | 6.0 |
Myelodysplastic Syndromes/*genetics | 3 | 4.0 |
Child | 4 | 0.0 |
*Chromosomes, Human, Pair 21 | 3 | 1.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
DNA-Binding Proteins/*genetics/physiology | 2 | 2.0 |
Proteins/genetics | 2 | 0.0 |
*Zinc Fingers | 4 | 1.0 |
Chromosome Disorders | 2 | 0.0 |
Chimeric Proteins/genetics | 2 | 3.0 |
Introns | 2 | 0.0 |
Inversion, Chromosome | 2 | 3.0 |
RNA, Messenger/genetics | 5 | 0.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Blast Crisis/*genetics | 2 | 15.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Gene Rearrangement | 6 | 1.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Oncogenes | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Survival Analysis | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*genetics/*metabolism | 2 | 66.0 |
Myelodysplastic Syndromes/*genetics/*metabolism | 2 | 100.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Rats | 2 | 0.0 |
Blotting, Southern | 3 | 0.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Chromosomes, Human, Pair 3/*genetics/ultrastructure | 3 | 30.0 |
Disease Progression | 2 | 0.0 |
Leukemia, Myeloid, Philadelphia-Positive/genetics | 2 | 13.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 3 | 2.0 |
RNA Splicing | 2 | 0.0 |
Transcription Factors/biosynthesis/*genetics | 2 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Zinc Fingers/*genetics | 2 | 1.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
RNA-Binding Proteins/genetics | 2 | 3.0 |
*Ribosomal Proteins | 2 | 8.0 |
Hematopoiesis | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
NIH 3T3 Cells | 2 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
